We conducted a randomized , parallel-group , double-blind , placebo-controlled study using a dose-escalation design to test @ clinically feasible doses of intranasal oxytocin ( @ , @ , or @ IU ) administered twice daily for @ week to @ patients with behavioral variant FTD or semantic dementia ( clinicaltrials.gov registration number NCT@ ) .